Shenzhen Tuwei Anchuang Technology Development Co., Ltd. was established in 2016, jointly funded by a team of overseas high-level talents and angel investors.

Innovative polypeptide drugs focusing on anti organ fibrosis, anti inflammation, immunity and metabolism, including polypeptide drugs for the treatment of liver fibrosis/cirrhosis (including viral liver fibrosis, NASH with liver fibrosis, PBC and PSC), pulmonary fibrosis (including IPF, radiation pneumonia with lung fibrosis and COPD), diabetes and kidney disease.